drugset / Trial / NCT07462507

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT07462507 ↗

Phase 2 Recruiting 104 enrolled Washington University School of Medicine
NaSingle-groupOpen-labelDiagnostic

Summary

Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.

Timeline

Start
2026-04-16
Primary completion
2031-06-30
Completion
2033-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject [C-11]-CS1P1 Diagnostic / imaging agent — Intravenous